Quick Facts

What Is Mounjaro?

Mounjaro is the brand name for tirzepatide, a prescription injectable medication manufactured by Eli Lilly. It belongs to an entirely new class of metabolic medications: dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonists.

Both GIP and GLP-1 are naturally occurring gut hormones released after eating. They work together to regulate appetite, blood sugar, and energy metabolism. By activating both receptor types simultaneously, Mounjaro produces a stronger and more comprehensive metabolic response than GLP-1 only medications like Wegovy or Ozempic.

Mounjaro is FDA-approved for the management of type 2 diabetes. Tirzepatide, its active ingredient, has received separate FDA approval for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. It is a prescription-only medication requiring clinical assessment and ongoing medical supervision.

Cost of Mounjaro in Abu Dhabi

Each box contains four pre-filled KwikPen doses. Dosage is titrated upward gradually under physician guidance based on your response and tolerability. Final pricing and dosage prescription are confirmed at your initial medical consultation.

The Mounjaro KwikPen Family

Mounjaro is delivered via the KwikPen, a pre-filled, multi-dose subcutaneous injection pen designed for once-weekly self-administration. Six dosage strengths are available, each corresponding to a phase of the structured titration schedule:

Dose escalation follows a structured schedule. Most patients increase every four weeks, though the pace is adjusted based on individual response, tolerability, and physician guidance.

How Does Mounjaro Work?

Mounjaro works by mimicking two gut hormones, GIP and GLP-1, that are naturally released in response to eating. By activating both receptor types simultaneously, it produces a coordinated metabolic response across several pathways:

Appetite suppression: GLP-1 receptor activation signals the brain's appetite-regulating centres to reduce hunger and increase the sense of fullness after smaller amounts of food. GIP receptor activation amplifies this effect.

Slowed gastric emptying: Mounjaro slows the rate at which the stomach empties into the small intestine. Food remains in the stomach longer, which extends the feeling of fullness between meals and reduces the frequency and intensity of hunger signals.

Blood sugar regulation: Both GIP and GLP-1 stimulate insulin secretion in response to elevated blood glucose and suppress glucagon (the hormone that raises blood sugar). This produces better blood sugar control with a lower risk of hypoglycemia compared to older diabetes medications.

Fat metabolism: The combination of reduced calorie intake from appetite suppression and improved insulin sensitivity supports progressive fat loss over the weeks and months of treatment.

The dual mechanism is what distinguishes Mounjaro from all other available injectables. Clinical trial data consistently show greater weight loss outcomes with tirzepatide than with semaglutide or liraglutide across comparable patient groups.

Who Is Eligible for Mounjaro?

Mounjaro is appropriate for adults who meet the following criteria:

1. Adults with type 2 diabetes looking to improve glycaemic control alongside lifestyle measures
2. Adults with a BMI of 30 or above seeking chronic weight management
3. Adults with a BMI of 27 or above, accompanied by at least one weight-related health condition such as high blood pressure, dyslipidemia, or sleep apnoea
4. Individuals are committed to combining the medication with dietary modification and regular physical activity

Mounjaro should be avoided by patients who have:

1. A personal or family history of medullary thyroid carcinoma (MTC)
2. Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
3. A history of severe allergic reactions to tirzepatide or any component of the formulation
4. Active pancreatitis or a significant history of pancreatitis
5. Active gallbladder disease
6. Severe gastrointestinal conditions that may be worsened by slowed gastric motility
7. Current pregnancy or breastfeeding
8. Age under 18 years

A full medical assessment is conducted before any prescription is issued. Mounjaro is not dispensed without clinical evaluation.

Steps of Mounjaro Treatment

How Much Weight Can You Expect to Lose?

Weight loss with Mounjaro varies based on the dose reached, the duration of treatment, and how well dietary and lifestyle modifications are maintained alongside the medication. The following timeline reflects outcomes documented in clinical trials:

These figures are based on the SURMOUNT clinical trial programme. Individual results vary. Patients who maintain dietary changes and regular physical activity alongside the medication consistently achieve better outcomes than those using medication alone.

How Does Weight Loss Help with Type 2 Diabetes?

Excess body weight is one of the primary drivers of insulin resistance, the condition in which cells become less responsive to insulin, causing blood sugar to rise. Weight loss directly improves insulin sensitivity, and Mounjaro addresses this through both its appetite-suppressing and direct receptor-mediated effects on insulin secretion.

The clinical benefits extend beyond blood sugar control:

1. Reduced insulin resistance as body fat decreases, particularly visceral (abdominal) fat
2. Lower blood pressure and improved lipid profiles as body weight reduces
3. Reduction in systemic inflammation, which is linked to both diabetes progression and cardiovascular risk
4. Reduced risk of diabetes-related complications, including kidney disease and non-alcoholic fatty liver disease
5. Potential for reduced reliance on additional diabetes medications as glycaemic control improves

Mounjaro is not a cure for type 2 diabetes. It is a highly effective management tool that works best as part of a structured programme including dietary guidance, physical activity, and regular clinical monitoring.

How to Get the Most from Mounjaro

Mounjaro works through the body's appetite and metabolic hormonal system. Its effectiveness is significantly enhanced by dietary choices that support rather than undermine the metabolic changes it produces.

Foods to Prioritize

1. Lean protein sources: chicken, fish, eggs, legumes. Protein supports satiety and preserves muscle mass during weight loss
2. Fibre-rich foods: vegetables, whole grains, and pulses. Fibre slows digestion and complements the gastric emptying effect of Mounjaro
3. Low-glycaemic carbohydrates: oats, brown rice, whole grain bread, these produce a slower, more stable blood sugar response
4. Hydration: adequate water intake supports kidney function and the metabolic clearance that accompanies weight loss

Foods to Limit

1. High-glycaemic fruits and refined sugars: fruit juices, sweets, sodas, and candies spike blood glucose rapidly
2. Processed and fried foods: high in saturated fat and calories, they counteract the calorie deficit the medication helps create
3. Alcohol: contributes excess calories, disrupts sleep quality, and can interact with blood sugar regulation
4. Highly processed carbohydrates: white bread, pasta, and pastries offer low nutritional value and produce rapid blood glucose rises

Physical Activity

Regular physical activity at least 150 minutes of moderate intensity per week, enhances insulin sensitivity, preserves lean muscle mass during weight loss, and amplifies the metabolic improvements Mounjaro produces. Your physician will advise on an appropriate activity level based on your current health and fitness.

Dosage Guide: Which Dose Is Right for You?

Mounjaro treatment always begins at 2.5 mg once weekly. This starting dose is not a therapeutic weight loss dose; it is an acclimatization phase designed to allow the body to adjust to the medication and minimize gastrointestinal side effects before the dose is increased.

2.5 mg (Weeks 1 to 4): Starting dose. Focuses on tolerability rather than significant weight loss. Most patients experience only mild nausea, if any, at this stage.

5 mg (Weeks 5 to 8): The first true therapeutic dose. Meaningful appetite suppression becomes established. Clinical data show significant weight loss beginning at this dose level. An excellent long-term maintenance dose for patients who achieve their goals here.

7.5 mg to 10 mg (Months 3 to 6): Escalation phase. Progressive increases in appetite suppression and weight loss outcomes. Most patients achieve their best results by this phase.

12.5 mg to 15 mg (Month 6 and beyond): Advanced and maximum therapeutic doses. Reserved for patients who have tolerated lower doses well and need further dose escalation to reach their weight loss targets. Clinical data show the greatest average weight loss at the 15 mg dose.

Dose escalation decisions are made by your physician at each follow-up appointment based on your response, tolerability, and progress toward your treatment goals.

Clinical Evidence: The SURMOUNT Trial Programme

Mounjaro's efficacy for weight loss is supported by one of the most comprehensive clinical trial programmes for any weight management medication. The SURMOUNT trials, published in The New England Journal of Medicine, demonstrate consistent, significant weight loss across diverse patient populations:

Key findings from the trial data:

1. Mounjaro's dual GIP and GLP-1 receptor mechanism consistently produced greater weight loss than single-receptor GLP-1 medications across all compared groups
2. The 10 mg and 15 mg doses produced the greatest average weight reduction
3. Participants also demonstrated significant improvements in blood pressure, lipid profiles, and glycaemic control beyond the weight loss itself

Mounjaro Regulation in Abu Dhabi

The Department of Health in Abu Dhabi maintains strict oversight of tirzepatide distribution and prescribing to ensure patient safety. The following regulatory requirements apply to all patients in the emirate:

1. Mounjaro requires a valid prescription from a DOH-licensed physician. Video prescriptions from licensed practitioners are accepted
2. The medication must be purchased through an authorized pharmacy or healthcare provider, not through informal channels or online marketplaces
3. Patients should be aware of counterfeit products circulating in some markets; always verify the source and check packaging integrity before use
4. Storage in Abu Dhabi's climate requires strict cold-chain adherence: refrigerate between 2 and 8 degrees Celsius; at room temperature (up to 30 degrees), the pen may be stored for a maximum of 21 days
5. If travelling with Mounjaro, carry the prescription as documentation

Mounjaro vs Other Weight Loss Injectables

For most patients seeking maximum weight loss outcomes, Mounjaro's dual mechanism produces superior results. For patients with specific medical profiles or tolerability concerns, Wegovy or Saxenda may be more appropriate. Your physician will confirm the most suitable option at the consultation.

How to Self-Inject with the Mounjaro KwikPen

After your first clinic session, a qualified nurse provides guidance on self-injection technique before you administer independently. The process is straightforward:

1. Wash your hands thoroughly before handling the pen.
2. Remove the KwikPen from the refrigerator approximately 30 minutes before injection to allow it to reach room temperature.
3. Inspect the pen to confirm the medication is clear and colourless. Do not use it if discoloured or cloudy.
4. Attach a new needle to the pen and remove the outer and inner protective caps.
5. Select an injection site: abdomen, upper thigh, or upper arm; rotate the site each week.
6. Clean the injection site with an alcohol swab and allow it to dry completely.
7. Pinch a fold of skin and hold the KwikPen at a 90-degree angle against the surface.
8. Press the injection button firmly and hold in place until the full dose is delivered and the pen clicks.
9. Remove the pen, recap the needle, and dispose of it in a sharps container.
10. Do not rub the injection site after administration.

Side Effects of Mounjaro

Mounjaro is well-tolerated by most patients. Side effects are most common during the initial weeks of each dose escalation and typically reduce as the body adjusts. The majority are gastrointestinal, a direct consequence of the medication slowing gastric emptying.

Common side effects (most frequent during dose escalation):

1. Nausea the most frequently reported effect; usually mild and peaks in the first 1 to 2 weeks at each new dose
2. Diarrhea or constipation
3. Indigestion and heartburn
4. Reduced appetite (expected and part of the therapeutic effect)
5. Fatigue, particularly in the first few weeks

Less common side effects:

1. Injection site reactions: redness, bruising, or itching
2. Belching or bloating

Rare but clinically significant, contact your physician immediately if you experience:

1. Severe or persistent abdominal pain (possible pancreatitis)
2. Signs of a serious allergic reaction: rash, swelling of the face or throat, difficulty breathing
3. Changes in vision
4. Rapid heartbeat or racing pulse
5. Signs of low blood sugar if combined with insulin or sulphonylurea medications

Why Choose Us for Mounjaro Treatment in Abu Dhabi?

Mounjaro is a powerful prescription medication that requires appropriate clinical oversight to use safely and effectively. The dose titration schedule, monitoring requirements, and management of side effects all depend on the quality of medical supervision provided.